Women's Health Practices: OB/GYN Exit Guide with 8-11x Benchmarks
Women's health has emerged as one of the most attractive verticals in healthcare M&A. Strategic buyers and private equity platforms are actively acquiring OB/GYN practices, fertility clinics, and women's wellness centers to build comprehensive women's health platforms. For practice owners in the $2M to $20M revenue range, this creates significant exit opportunities. Well-positioned practices are commanding 8x to 11x EBITDA, multiples that were rare just a few years ago.
Why Women's Health Is Attracting Premium Valuations
Several factors have converged to make women's health one of the hottest M&A verticals. PE-backed platforms like Unified Women's Healthcare, Women's Care, and US Women's Health have raised significant capital to consolidate the fragmented women's health market and are actively acquiring to build scale. Buyers want to offer the full spectrum of women's health services including OB/GYN, fertility, urogynecology, breast health, and wellness, and practices that fill gaps in existing platforms command premiums. Women control 80% of healthcare spending decisions and are increasingly seeking integrated, convenient care. Unlike some healthcare verticals facing reimbursement pressure, women's health services maintain relatively stable payor dynamics. Practices can also generate significant revenue from ancillary services including ultrasound, lab, aesthetics, and wellness that improve margins.
Current Multiples for Women's Health Practices
| Practice Profile | Typical EBITDA Multiple |
|---|---|
| Solo OB/GYN, single location | 4x to 6x |
| Group practice, 3 to 5 providers | 6x to 8x |
| Multi-location with ancillaries | 8x to 10x |
| Platform-ready (scale plus subspecialties) | 9x to 11x+ |
| Fertility clinics (standalone) | 10x to 14x |
What Drives 8 to 11x Multiples
Scale and provider depth are the primary drivers. Platform buyers want practices that can anchor a market or fill geographic gaps. Multi-provider practices with established patient bases and growth potential are significantly more valuable than solo operations. The threshold for premium valuations typically starts at 3 or more providers and $1M or more in EBITDA. Subspecialty services command premiums: fertility and REI is the highest-value subspecialty often commanding 10x to 14x standalone, urogynecology has growing demand and limited supply, maternal-fetal medicine expertise is valuable to platforms, and minimally invasive gynecologic surgery differentiates the practice.
Ancillary revenue streams are highly valued. Practices with 20% or more of revenue from ancillaries including in-office ultrasound and imaging, laboratory services, medical aesthetics, weight management programs, and hormone therapy typically command 1 to 2 additional multiple turns compared to those without. Buyers also prefer practices with balanced payor mixes across commercial insurance, Medicare, and self-pay. Practices where a single physician generates most of the revenue face key-person risk discounts. Documented workflows, EHR optimization, revenue cycle efficiency, and compliance programs signal operational maturity that buyers pay more for.
Case Study: Valuation Impact of Preparation
Consider two OB/GYN practices with similar revenue. Practice A has a solo physician, no ancillaries, and the owner performs 90% of deliveries, commanding a 4.5x multiple. Practice B has four physicians, ultrasound and lab in-house, shared call coverage, and documented systems, commanding a 9x multiple. With $600K in EBITDA, Practice A is worth $2.7M while Practice B is worth $5.4M, double the value for similar top-line revenue. The difference is not luck. It is positioning.
If you are exploring a sale of your women's health practice, schedule a confidential valuation consultation with our team.
FAQs
Why are fertility clinics valued higher than general OB/GYN practices?
Fertility services have higher revenue per patient, strong growth trends, and limited competition due to subspecialty training requirements. Fertility clinics also attract affluent cash-pay patients. These factors drive premiums of 10x to 14x EBITDA.
Can I sell a solo OB/GYN practice?
Yes, but valuations will be lower at 4x to 6x due to key-person risk and limited scale. Buyers are typically other physicians, small groups, or platforms looking for tuck-in acquisitions.
Do I need to add providers before selling?
Not necessarily, but multi-provider practices command higher multiples and attract more buyer interest. If you have time of 18 to 24 months, adding an associate can meaningfully improve your valuation.
What transition period should I expect?
Most deals require 12 to 24 months of transition, particularly for practices with strong physician-patient relationships. Shorter transitions may be possible with strong provider teams and documented systems.
Recommended Reading
- Healthcare Practice Valuation Multiples 2026: What Is Your Clinic Worth? — Broad healthcare sector benchmarks across all major specialties.
- Private Equity Rollovers: How to Sell Your Company Twice — Understand equity rollover structures common in women's health deals.
- How to Sell Your Business to Private Equity — How PE platforms work and what to expect from financial buyers.
- EBITDA Multiples by Industry (2026) — Cross-industry context for healthcare valuations.
- Home Care Agency Valuation Multiples 2026 — An adjacent healthcare sector valuation guide.
Key Takeaways
- Women's health practices are commanding 8x to 11x EBITDA multiples as PE platforms build comprehensive care networks.
- Fertility clinics trade at the highest multiples (10x to 14x) due to growth, margins, and specialty barriers.
- Ancillary services including ultrasound, lab, and aesthetics can add 1 to 2 multiple turns to your valuation.
- Multi-provider practices with shared patient relationships are significantly more valuable than solo operations.
- Platform building is active in 2026, but consolidation windows do not stay open indefinitely.
- Start preparation 12 to 24 months before your target exit to build provider depth and ancillary revenue.